High level HPV-16 E7 oncoprotein expression correlates with reduced pRb-levels in cervical biopsies MARC FIEDLER * ,† , ELISABETH MÜLLER-HOLZNER ‡ , HANS-PETER VIERTLER 1 , ANDREAS WIDSCHWENDTER ‡ , ANDREAS LAICH * ,† , GERALD PFISTER † , GILLES A. SPODEN * , PIDDER JANSEN-DÜRR † and WERNER ZWERSCHKE * ,† ,1 * Tyrolean Cancer Research Institute at the University of Innsbruck, 6020 Innsbruck, Austria; † Institute for Biomedical Aging Research of the Austrian Academy of Sciences, Innsbruck, Austria; and ‡ Department of Obstetrics and Gynecology, University of Innsbruck, Innsbruck, Austria 1 Correspondence: Tyrolean Cancer Research Institute and Institute for Biomedical Aging Research, Innrain 66, 6020 Innsbruck, Austria. E-mail: werner.zwerschke@uklibk.ac.at <h3>SPECIFIC AIMS</h3> E7, the major transforming oncogene of HPV-16, codes for an unstable protein whose abundance in cervical biopsies is presently unknown. Using highly specific anti-HPV-16 E7 antibodies, we examined the expression level and subcellular localization of the E7 protein in cervical carcinogenesis in situ and analyzed whether E7-driven degradation of pRb is involved in cervical tumorigenesis in humans. <h3>PRINCIPAL FINDINGS</h3> <h3>1. Generation of polyclonal anti-HPV-16 E7 antibodies</h3> To obtain antibodies to HPV-16 E7 suitable for E7 in situ detection, we immunized rabbits with highly purified native
/lp/fed-of-american-socs-for-experimental-biology/high-level-hpv-16-e7-oncoprotein-expression-correlates-with-reduced-IUk2UHanHD